Evidence map›Paper›PMID 38577307›Full record

ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2023

Leveraging the Million Veteran Program Infrastructure and Data for a Rapid Research Response to COVID-19.

Stacey B Whitbourne, Jennifer Moser, Kelly Cho, Jennifer Deen, Lori L Churby, Amy C Justice, Juan P Casas, Saiju Pyarajan, Phil S Tsao, J Michael Gaziano and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. The VA Research Enterprise: A Platform for National Partnerships Toward Evidence Building and Scientific Innovation.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Stacey B WhitbourneVeterans Affairs Boston Healthcare System, Massachusetts.
Jennifer MoserOffice of Research and Development, Department of Veterans Affairs, Washington, DC.
Kelly ChoVeterans Affairs Boston Healthcare System, Massachusetts.
Jennifer DeenOffice of Research and Development, Department of Veterans Affairs, Washington, DC.
Lori L ChurbyVeterans Affairs Palo Alto Healthcare System, California.
Amy C JusticeVeterans Affairs Connecticut Healthcare System, West Haven.
Juan P CasasNovartis Institute for Biomedical Research, Cambridge, Massachusetts.
Saiju PyarajanVeterans Affairs Boston Healthcare System, Massachusetts.
Phil S TsaoVeterans Affairs Palo Alto Healthcare System, California.
J Michael GazianoVeterans Affairs Boston Healthcare System, Massachusetts.
Sumitra MuralidharOffice of Research and Development, Department of Veterans Affairs, Washington, DC.
Brigham and Women's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The Veterans Health Administration Office of Research and Development (ORD) played a key role in the federal government's response to the COVID-19 pandemic. The ORD effectively leveraged existing resources to answer questions related to the SARS-CoV-2 virus and COVID-19. Observations: When the COVID-19 pandemic hit in 2020, the Million Veteran Program (MVP), one of the largest genomic cohorts in the world, extended the centralized recruitment and enrollment infrastructure to develop a COVID-19 research volunteer registry to assist enrollment in the vaccine and treatment trials in which the US Department of Veterans Affairs (VA) participated. In addition, the MVP allowed for new data collection and a large genomic cohort to understand host contributions to COVID-19. This article describes ways the MVP contributed to the VA's rapid research response to COVID-19. Several host genetic factors believed to play a role in the development and severity of COVID-19 were identified. Furthermore, existing MVP partnerships with other federal agencies, particularly with the Department of Energy, were leveraged to improve understanding and management of COVID-19. Conclusions: A previously established enterprise approach and research infrastructure were essential to the VA's successful and timely COVID-19 research response. This infrastructure not only supported rapid recruitment in vaccine and treatment trials, but also leveraged the unique MVP and VA electronic health record data to drive rapid scientific discovery and inform clinical operations. Extending the models that VA research applied to the federal government at large and establishing centralized resources for shared or federated data analyses across federal agencies will better equip the nation to respond to future public health crises.

Identifiers

PMID38577307
PMCPMC10988626
OpenAlexW4388142138

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.